| Name | Title | Contact Details |
|---|
Mednational is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1981, Sunrise Senior Living is credited with establishing the modern era of senior living. Each Sunrise community is dedicated to delivering a personalized approach to senior living where every aspect of the services and environment is built around the specific wants and needs of the individual seniors that call the community home. From purposefully created and thoughtful design, to engaging programming and lifestyle activities and best-in-class quality of care that evolves with the needs of each senior, Sunrise`s industry-leading innovation is built upon its mission to champion quality of life for all seniors. Celebrating 40 years, Sunrise operates more than 240 communities in the United States and Canada serving more than 20,000 residents. With more than 20,000 highly trained team members, Sunrise offers a full range of personalized services, including independent living, assisted living, care for individuals with Alzheimer`s and other forms of dementia, as well as nursing and rehabilitative services.
VisuWell is the leader in patient-centered, innovative, and affordable virtual care solutions. The VisuWell platform is an easy-to-use, enterprise-ready, browser-deployed technology increasing healthcare access for health systems, ambulatory care organizations, and payors. VisuWell offers patients and providers a comprehensive telehealth experience for consults, triage, telemedicine visits, and remote patient monitoring over a wide variety of use cases and environments. VisuWell enables care organizations to utilize their own provider networks to offer easy-to-access, high-quality care. The VisuWell platform creates a tailored virtual experience accommodating 35+ use cases serving thousands of locations and helping millions of people to see healthcare differently.
Lasik MD is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.